Arkolith/Insider Trading/AZRX/Form 4

Schneiderman Daniel H

CHIEF FINANCIAL OFFICERAzurRx BioPharma, Inc. (AZRX) · full profile →Form 4 · filed Jul 2, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2021Grant(A)35K—$035K
Jun 30, 2021Grant(A)250K—$0250K
Jun 30, 2021Other(J)250K—$00
Jun 30, 2021Other(J)35K—$00

Transaction Codes

A
Grant / award
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-21-003429) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML